IFLR1000

Becton Dickinson & Co $24 billion acquisition of CR Bard

23/4/2017
Public acquisition
Select tab

$ 24 billion

Announced

23/4/2017

Overview:

  • Becton Dickinson & Co has acquired fellow healthcare supplier CR Bard in a $24 billion deal.
  • BD paid $317 in cash and stock per CR Bard share.
  • The transaction is being financed with a combination of available cash, new debt and new equity offerings.
  • The deal comes less than six months after another high-profile M&A transaction in the healthcare sector: Johnson & Johnson's acquisition of Actelion.
  • The transaction is expected to close in fall 2017.

Kurt Stumpo - Journalist

Jurisdiction:

United States

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Healthcare

Firms:
Fried Frank Harris Shriver & Jacobson

Party: Goldman Sachs (Financial adviser)

Lawyers: Philip Richter, Steven Epstein

Skadden Arps Slate Meagher & Flom

Party: Becton Dickinson & Co (Acquirer)

Lawyers: Michael Chitwood, Paul Schnell, Ryan Dzierniejko, Steven Messina, Thomas Greenberg

Wachtell Lipton Rosen & Katz

Party: CR Bard (Target)

Lawyers: Edward Herlihy, Gregory Pessin

Weil Gotshal & Manges

Party: Citigroup (Financial adviser)

Lawyer: Raymond Gietz

Related deals